Impact of Atorvastatin on Prostate Cancer Progression During ADT

PHASE3RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

August 15, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Metastatic Prostate CancerRecurrent Prostate Cancer
Interventions
DRUG

Atorvastatin 80mg

Capsules including 80 mg of atorvastatin

DRUG

Placebo oral capsule

Similar capsules as in the atorvastatin arm, but without the active ingredient

Trial Locations (10)

Unknown

NOT_YET_RECRUITING

Herlev and Gentofte Hospital, Herlev

RECRUITING

Tartu University Hospital, Tartu

RECRUITING

Helsinki University Hospital, Department of Urology, Helsinki

RECRUITING

Central Finland central hospital, Jyväskylä

NOT_YET_RECRUITING

Kuopio University Hospital, Department of Urology, Kuopio

RECRUITING

Seinäjoki Central Hospital, Department of Surgery, Seinäjoki

RECRUITING

Tampere University Hospital, Tampere

RECRUITING

Turku University Hospital, Turku

RECRUITING

The Hospital of Telemark, Skien

RECRUITING

The Hospital of Vestfold, Tønsberg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Turku University Hospital

OTHER_GOV

collaborator

Central Finland Hospital District

OTHER

collaborator

Tartu University Hospital

OTHER

collaborator

University of Aarhus

OTHER

collaborator

Fimlab laboratories

UNKNOWN

collaborator

Helsinki University Central Hospital

OTHER

collaborator

Kuopio University Hospital

OTHER

collaborator

Oulu University Hospital

OTHER

collaborator

Seinajoki Central Hospital

OTHER

collaborator

The Hospital of Vestfold

OTHER

collaborator

Telemark Hospital Trust

UNKNOWN

lead

Tampere University Hospital

OTHER